Researchers reveal why analyses of cancer-causing mutations are riddled with false positives and demonstrate a new approach that eliminates the problem.
The head of GlaxoSmithKline’s Shanghai neurodegenerative-disease research unit is axed after irregularities are uncovered in a 2010 paper he published.